ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » California » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in California

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
ANIL MOHIN M.D.

Cardiovascular Disease

6,001

$566K

380
276 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

4%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

42%
prescriptions for brand name drugs

Avg: 28%

$94
Average prescription price

Avg: $67

CHARLES OKONKWO M.D.

Cardiovascular Disease

6,422

$566K

142
106 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

54%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

43%
prescriptions for brand name drugs

Avg: 28%

$88
Average prescription price

Avg: $67

MOHINDER POONIA MD

Cardiovascular Disease

9,978

$564K

402
308 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

23%
patients receiving schedule three controlled substances

Avg: 2%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 28%

$57
Average prescription price

Avg: $67

MARC EFFRON M.D.

Cardiovascular Disease

6,284

$563K

467
446 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

40%
prescriptions for brand name drugs

Avg: 28%

$90
Average prescription price

Avg: $67

WILLIAM ALTON M.D.

Cardiovascular Disease

8,467

$562K

532
502 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 28%

$66
Average prescription price

Avg: $67

BYRON J ALLEN MD

Cardiovascular Disease

6,733

$561K

413
363 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

36%
prescriptions for brand name drugs

Avg: 28%

$83
Average prescription price

Avg: $67

JIVAN MELIKIAN M.D.

Cardiovascular Disease

10,889

$558K

528
500 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

44%
prescriptions for brand name drugs

Avg: 28%

$51
Average prescription price

Avg: $67

ADITYA VERMA M.D.

Cardiovascular Disease

5,210

$556K

594
556 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

38%
prescriptions for brand name drugs

Avg: 28%

$107
Average prescription price

Avg: $67

JANE KAUFFMAN M,D.

Cardiovascular Disease

9,500

$554K

560
534 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

4%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

43%
prescriptions for brand name drugs

Avg: 28%

$58
Average prescription price

Avg: $67

MEHRAN MOUSSAVIAN DO

Cardiovascular Disease

12,856

$548K

1105
959 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 28%

$43
Average prescription price

Avg: $67

ZOUHEIR ELIAS MD

Cardiovascular Disease

5,765

$545K

603
549 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 28%

$95
Average prescription price

Avg: $67

TOURAGE SOLEIMANI MD

Cardiovascular Disease

7,623

$540K

385
367 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

45%
prescriptions for brand name drugs

Avg: 28%

$71
Average prescription price

Avg: $67

THAI NGUYEN M.D.

Cardiovascular Disease

16,878

$535K

638
575 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

4%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 28%

$32
Average prescription price

Avg: $67

MARTIN CHARLAT M.D.

Cardiovascular Disease

6,507

$535K

634
585 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

34%
prescriptions for brand name drugs

Avg: 28%

$82
Average prescription price

Avg: $67

FOWROOZ JOOLHAR M.D.

Cardiovascular Disease

5,587

$533K

239
222 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 28%

$95
Average prescription price

Avg: $67

VINOD MALHOTRA MD

Cardiovascular Disease

10,188

$531K

478
340 are 65+

9%
patients receiving schedule two controlled substances

Avg: 0%

22%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 28%

$52
Average prescription price

Avg: $67

KIRK CHANG M.D

Cardiovascular Disease

6,303

$531K

358
330 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

5%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

44%
prescriptions for brand name drugs

Avg: 28%

$84
Average prescription price

Avg: $67

JAMIL ABOULHOSN MD

Cardiovascular Disease

921

$529K

107
39 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

34%
prescriptions for brand name drugs

Avg: 28%

$575
Average prescription price

Avg: $67

JAMES LIES M.D.

Cardiovascular Disease

7,420

$526K

507
455 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 28%

$71
Average prescription price

Avg: $67

ANURADHA CHIRALA M.D., F.A.C.C.

Cardiovascular Disease

7,572

$524K

431
390 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

37%
prescriptions for brand name drugs

Avg: 28%

$69
Average prescription price

Avg: $67

NORBERTO WAISMAN M.D.

Cardiovascular Disease

7,997

$519K

365
337 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

11%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

37%
prescriptions for brand name drugs

Avg: 28%

$65
Average prescription price

Avg: $67

HED AHMADPOUR M.D.

Cardiovascular Disease

6,074

$517K

329
294 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

46%
prescriptions for brand name drugs

Avg: 28%

$85
Average prescription price

Avg: $67

STANLEY LAU M.D.

Cardiovascular Disease

11,873

$515K

1222
1157 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 28%

$43
Average prescription price

Avg: $67

THOMAS DOUGHERTY M.D.

Cardiovascular Disease

9,798

$514K

633
580 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

7%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

19%
prescriptions for brand name drugs

Avg: 28%

$52
Average prescription price

Avg: $67

ADRIAN SHANDLING MD

Cardiovascular Disease

4,952

$509K

279
247 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

9%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

35%
prescriptions for brand name drugs

Avg: 28%

$103
Average prescription price

Avg: $67

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank